Of interest to editors and journalists covering:
Business/Finance, Drugs/Pharmaceuticals, Biotech, Investments, MedTech


Health Discovery Corporation Announces Participation in the SCIA Conference

Savannah, Ga, April 7, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin
Board: HDVY) today announced that David Cooper, M.D., Ph.D., President and Chief Medical
Officer of Health Discovery Corporation, was one of the presenters at the Southern California
Investment Association conference on Saturday April 3rd which was held in Orange County, CA.
Dr. Cooper discussed the status of Health Discovery Corporation, a
genomic/proteomic/biotechnology company focused on biomarker and pathway discovery for
diagnostic markers and drug targets.

He indicated that the company is proceeding well with recently signed agreements with MD
Anderson Cancer Center, Stanford University and the University of Miami. These agreements,
which provide joint ownership of the biomarker discovery and/or rights to obtain worldwide
exclusive licenses to the discoveries, are focusing specifically on Prostate Cancer, Leukemia,
AIDS Related Dementia and Lymphatic Insufficiency. Additional relationships are to be announced
shortly.

He expects the Company to be profitable within about 18 months as their products and client
list continues to grow. Dr. Cooper indicated that whereas most companies in the
genomic/proteomic space are raising upwards of $100 million to fund their research, Health
Discovery Corporation's expected capital requirements will be small in comparison to several of
its competitors in this space because HDC identifies patient-specific commercially important
clinical problems and then establishes relationships with diagnostic and pharmaceutical
companies world-wide to facilitate a solution, whereas, other companies focus on general
discovery without a specific patient or illness in mind.

Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery
company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics
Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic
candidates. Focusing on disease vs. normal, within complex genomic, proteomic and clinical data
sets, Health Discovery Corporation was established to provide pharmaceutical and diagnostic
companies with a broad range of analytical and decision support solutions to accelerate
effective diagnostic and drug discovery. Founded in September 2003, the Company has offices in
Texas, Georgia, and California. For more information contact Robert S. Braswell IV of Health
Discovery Corporation +1-866-953-9031 or Info@healthdiscoverycorp.com.

This news release contains "forward-looking statements" within the meaning of Section 27a of
the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although
the Company believes that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

More information: http://www.healthdiscoverycorp.com




Copr. © 2004 Send2Press™